Annual EBITDA
-$313.91 M
+$131.23 M+29.48%
December 31, 2024
Summary
- As of February 26, 2025, ASND annual EBITDA is -$313.91 million, with the most recent change of +$131.23 million (+29.48%) on December 31, 2024.
- During the last 3 years, ASND annual EBITDA has risen by +$117.53 million (+27.24%).
- ASND annual EBITDA is now -4718.17% below its all-time high of $6.80 million, reached on December 31, 2013.
Performance
ASND EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$40.39 M
+$37.84 M+48.37%
December 31, 2024
Summary
- As of February 26, 2025, ASND quarterly EBITDA is -$40.39 million, with the most recent change of +$37.84 million (+48.37%) on December 31, 2024.
- Over the past year, ASND quarterly EBITDA has increased by +$56.01 million (+58.10%).
- ASND quarterly EBITDA is now -1818.08% below its all-time high of $2.35 million, reached on December 31, 2013.
Performance
ASND Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$265.95 M
+$32.50 M+10.89%
December 31, 2024
Summary
- As of February 26, 2025, ASND TTM EBITDA is -$265.95 million, with the most recent change of +$32.50 million (+10.89%) on December 31, 2024.
- Over the past year, ASND TTM EBITDA has increased by +$98.33 million (+26.99%).
- ASND TTM EBITDA is now -11412.17% below its all-time high of $2.35 million, reached on December 31, 2013.
Performance
ASND TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ASND EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +29.5% | +58.1% | +27.0% |
| 3 y3 years | +27.2% | +58.1% | +27.0% |
| 5 y5 years | -33.3% | +58.1% | +27.0% |
ASND EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +43.8% | at high | +79.4% | at high | +52.5% |
| 5 y | 5-year | -33.3% | +43.8% | at high | +80.6% | -17.6% | +52.5% |
| alltime | all time | -4718.2% | +43.8% | -1818.1% | +80.6% | <-9999.0% | +52.5% |
Ascendis Pharma A/S EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$313.91 M(-29.5%) | -$40.39 M(-48.4%) | -$265.95 M(-10.9%) |
| Sep 2024 | - | -$78.23 M(-18.8%) | -$298.45 M(-18.1%) |
| Jun 2024 | - | -$96.40 M(+89.3%) | -$364.28 M(-5.5%) |
| Mar 2024 | - | -$50.93 M(-30.1%) | -$385.53 M(-11.8%) |
| Dec 2023 | -$445.13 M(-20.2%) | -$72.89 M(-49.4%) | -$436.88 M(-22.0%) |
| Sep 2023 | - | -$144.06 M(+22.5%) | -$560.44 M(+3.7%) |
| Jun 2023 | - | -$117.64 M(+15.0%) | -$540.65 M(+9.2%) |
| Mar 2023 | - | -$102.28 M(-47.9%) | -$494.95 M(-5.2%) |
| Dec 2022 | -$558.07 M(+29.4%) | -$196.46 M(+58.1%) | -$522.21 M(+18.5%) |
| Sep 2022 | - | -$124.27 M(+72.7%) | -$440.78 M(+8.6%) |
| Jun 2022 | - | -$71.94 M(-44.5%) | -$405.74 M(-14.9%) |
| Mar 2022 | - | -$129.54 M(+12.6%) | -$476.83 M(+14.2%) |
| Dec 2021 | -$431.44 M(-7.4%) | -$115.02 M(+28.9%) | -$417.66 M(-18.2%) |
| Sep 2021 | - | -$89.23 M(-37.6%) | -$510.66 M(-0.7%) |
| Jun 2021 | - | -$143.03 M(+103.2%) | -$514.42 M(+11.3%) |
| Mar 2021 | - | -$70.37 M(-66.2%) | -$462.29 M(+0.7%) |
| Dec 2020 | -$465.73 M(+97.8%) | -$208.02 M(+123.7%) | -$459.19 M(+36.0%) |
| Sep 2020 | - | -$92.99 M(+2.3%) | -$337.56 M(+25.0%) |
| Jun 2020 | - | -$90.91 M(+35.2%) | -$270.02 M(+15.3%) |
| Mar 2020 | - | -$67.27 M(-22.1%) | -$234.12 M(+3.5%) |
| Dec 2019 | -$235.48 M | -$86.39 M(+239.4%) | -$226.17 M(+28.5%) |
| Sep 2019 | - | -$25.45 M(-53.7%) | -$176.00 M(-7.3%) |
| Jun 2019 | - | -$55.01 M(-7.3%) | -$189.84 M(+17.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$59.32 M(+63.8%) | -$161.89 M(+11.9%) |
| Dec 2018 | -$152.90 M(+9.3%) | -$36.22 M(-7.8%) | -$144.68 M(-10.3%) |
| Sep 2018 | - | -$39.29 M(+45.1%) | -$161.26 M(+1.7%) |
| Jun 2018 | - | -$27.07 M(-35.7%) | -$158.55 M(+0.2%) |
| Mar 2018 | - | -$42.11 M(-20.2%) | -$158.25 M(+12.3%) |
| Dec 2017 | -$139.91 M(+85.8%) | -$52.79 M(+44.3%) | -$140.93 M(+29.3%) |
| Sep 2017 | - | -$36.59 M(+36.7%) | -$109.02 M(+18.1%) |
| Jun 2017 | - | -$26.77 M(+8.0%) | -$92.30 M(+14.8%) |
| Mar 2017 | - | -$24.78 M(+18.7%) | -$80.42 M(+7.0%) |
| Dec 2016 | -$75.32 M(+105.6%) | -$20.88 M(+5.2%) | -$75.18 M(+6.6%) |
| Sep 2016 | - | -$19.86 M(+33.3%) | -$70.56 M(+20.6%) |
| Jun 2016 | - | -$14.90 M(-23.7%) | -$58.53 M(+1.5%) |
| Mar 2016 | - | -$19.54 M(+20.1%) | -$57.66 M(+58.8%) |
| Dec 2015 | -$36.63 M(+180.5%) | -$16.26 M(+107.7%) | -$36.32 M(+33.3%) |
| Sep 2015 | - | -$7.83 M(-44.2%) | -$27.25 M(+25.2%) |
| Jun 2015 | - | -$14.03 M(-877.4%) | -$21.76 M(+109.1%) |
| Mar 2015 | - | $1.81 M(-125.1%) | -$10.41 M(-17.9%) |
| Dec 2014 | -$13.06 M(-292.1%) | -$7.19 M(+206.4%) | -$12.68 M(+303.4%) |
| Sep 2014 | - | -$2.35 M(-12.4%) | -$3.14 M(+294.1%) |
| Jun 2014 | - | -$2.68 M(+470.0%) | -$797.50 K(-142.4%) |
| Mar 2014 | - | -$469.90 K(-120.0%) | $1.88 M(-20.0%) |
| Dec 2013 | $6.80 M(+205.6%) | $2.35 M | $2.35 M |
| Dec 2012 | $2.22 M | - | - |
FAQ
- What is Ascendis Pharma A/S annual EBITDA?
- What is the all time high annual EBITDA for Ascendis Pharma A/S?
- What is Ascendis Pharma A/S annual EBITDA year-on-year change?
- What is Ascendis Pharma A/S quarterly EBITDA?
- What is the all time high quarterly EBITDA for Ascendis Pharma A/S?
- What is Ascendis Pharma A/S quarterly EBITDA year-on-year change?
- What is Ascendis Pharma A/S TTM EBITDA?
- What is the all time high TTM EBITDA for Ascendis Pharma A/S?
- What is Ascendis Pharma A/S TTM EBITDA year-on-year change?
What is Ascendis Pharma A/S annual EBITDA?
The current annual EBITDA of ASND is -$313.91 M
What is the all time high annual EBITDA for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high annual EBITDA is $6.80 M
What is Ascendis Pharma A/S annual EBITDA year-on-year change?
Over the past year, ASND annual EBITDA has changed by +$131.23 M (+29.48%)
What is Ascendis Pharma A/S quarterly EBITDA?
The current quarterly EBITDA of ASND is -$40.39 M
What is the all time high quarterly EBITDA for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high quarterly EBITDA is $2.35 M
What is Ascendis Pharma A/S quarterly EBITDA year-on-year change?
Over the past year, ASND quarterly EBITDA has changed by +$56.01 M (+58.10%)
What is Ascendis Pharma A/S TTM EBITDA?
The current TTM EBITDA of ASND is -$265.95 M
What is the all time high TTM EBITDA for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high TTM EBITDA is $2.35 M
What is Ascendis Pharma A/S TTM EBITDA year-on-year change?
Over the past year, ASND TTM EBITDA has changed by +$98.33 M (+26.99%)